Jim Kastenmayer
General Counsel bei ARRIVENT BIOPHARMA, INC.
Vermögen: 114 778 $ am 30.04.2024
Aktive Positionen von Jim Kastenmayer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARRIVENT BIOPHARMA, INC. | General Counsel | 01.09.2023 | - |
Unternehmenssekretär | 01.09.2023 | - |
Karriereverlauf von Jim Kastenmayer
Ehemalige bekannte Positionen von Jim Kastenmayer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SPYRE THERAPEUTICS, INC. | Vorstandsvorsitzender | 24.08.2022 | 29.11.2022 |
General Counsel | 15.07.2021 | 16.05.2023 | |
Präsident | 24.08.2022 | 29.11.2022 | |
Unternehmenssekretär | 29.11.2022 | 16.05.2023 | |
VIELA BIO, INC. | General Counsel | 01.01.2020 | 01.03.2021 |
Unternehmenssekretär | 01.01.2020 | 01.03.2021 | |
ASTRAZENECA PLC | General Counsel | 01.05.2012 | 01.12.2019 |
Medimmune, Inc. | Corporate Officer/Principal | - | - |
Ausbildung von Jim Kastenmayer
Georgetown University Law Center | Graduate Degree |
Michigan State University | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Vereinigtes Königreich | 2 |
Operativ
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
SPYRE THERAPEUTICS, INC. | Health Technology |
ARRIVENT BIOPHARMA, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Medimmune, Inc. | Health Technology |
- Börse
- Insiders
- Jim Kastenmayer
- Erfahrung